Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 2/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6581604 | 0.80 | MMP9 (0.32) | MMP9MMP1MMP2 | |
| SCHEMBL6765429 | 0.80 | MMP9 (0.34) | MMP9MMP1MMP2 | |
| SCHEMBL2757777 | 0.80 | MMP9 (0.32) | MMP9MMP1MMP2 | |
| SCHEMBL2871627 | 0.78 | MMP9 (0.32) | MMP9MMP1MMP2 | |
| SCHEMBL13381148 | 0.78 | MMP9 (0.31) | MMP9MMP1MMP2 | |
| SCHEMBL13381185 | 0.74 | — | — | |
| SCHEMBL6765480 | 0.72 | MMP9 (0.35) | MMP9MMP1MMP2 | |
| SCHEMBL14429312 | 0.71 | — | — | |
| SCHEMBL14429313 | 0.70 | — | — | |
| SCHEMBL714279 | 0.69 | CHRM2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183394-B2 | Protease inhibitor precursor synthesis | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2012-05-22 | — | — | US | disclosed |
| US-8183394-B2 | Protease inhibitor precursor synthesis | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2012-05-22 | — | — | US | disclosed |
| US-20120041215-A1 | PROTEASE INHIBITOR PRECURSOR SYNTHESIS | JANSSEN SCIENCES IRELAND UC (IE) | 2012-02-16 | — | — | US | disclosed |
| US-20120041215-A1 | PROTEASE INHIBITOR PRECURSOR SYNTHESIS | JANSSEN SCIENCES IRELAND UC (IE) | 2012-02-16 | — | — | US | disclosed |
| US-8067463-B2 | Protease inhibitor precursor synthesis | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-11-29 | — | — | US | disclosed |
| US-8067463-B2 | Protease inhibitor precursor synthesis | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-11-29 | — | — | US | disclosed |
| EP-1856125-B1 | PROTEASE INHIBITOR PRECURSOR SYNTHESIS | TIBOTEC PHARM LTD (IE) | 2009-08-26 | — | — | EP | disclosed |
| US-20090054668-A1 | Protease inhibitor precursor synthesis | JANSSEN SCIENCES IRELAND UC (IE) | 2009-02-26 | — | — | US | disclosed |
| US-20090054668-A1 | Protease inhibitor precursor synthesis | JANSSEN SCIENCES IRELAND UC (IE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054668-A1 | Protease inhibitor precursor synthesis | SPINT2, PREP, PEPD | MMP9 375/4885MMP1 562/4885MMP2 153/4885 |
| US-20120041215-A1 | PROTEASE INHIBITOR PRECURSOR SYNTHESIS | SPINT2, PREP, PEPD | MMP9 375/4885MMP1 562/4885MMP2 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.